Literature DB >> 26143343

Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction.

Ayse L Mindikoglu1, Thomas C Dowling2, David J Schaub3, William R Hutson4, Darryn R Potosky4, Robert H Christenson5, Rolf N Barth6, John C LaMattina6, Steven I Hanish6, Matthew R Weir7, Jean-Pierre Raufman4.   

Abstract

Entities:  

Keywords:  Cirrhosis; Pharmacokinetics; Renal dysfunction; Sildenafil

Mesh：

Substances：

Year:  2015        PMID： 26143343      PMCID： PMC4623880          DOI： 10.1007/s10620-015-3771-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  14 in total

Review 1.  Endothelial regulation of vascular tone.

Authors:  P Vallance
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

2.  Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.

Authors:  P Deibert; Y-O Schumacher; G Ruecker; O G Opitz; H E Blum; M Rössle; W Kreisel
Journal:  Aliment Pharmacol Ther       Date:  2006-01-01       Impact factor: 8.171

3.  Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.

Authors:  Helle C Thiesson; Boye L Jensen; Bente Jespersen; Ove B Schaffalitzky de Muckadell; Claus Bistrup; Steen Walter; Peter D Ottosen; Annegrete Veje; Ole Skøtt
Journal:  Am J Physiol Renal Physiol       Date:  2004-12-21

4.  Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis.

Authors:  Rima Tahseldar-Roumieh; Rana Ghali-Ghoul; Claire Lugnier; Ramzi Sabra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-01       Impact factor: 4.733

5.  Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

Review 6.  Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.

Authors:  Anna R Hemnes; Hunter C Champion
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-05

7.  The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.

Authors:  Gary J Muirhead; Keith Wilner; Wayne Colburn; Gertrude Haug-Pihale; Bernhard Rouviex
Journal:  Br J Clin Pharmacol       Date:  2002       Impact factor: 4.335

8.  Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality.

Authors:  Donald J Nichols; Gary J Muirhead; Jane A Harness
Journal:  Br J Clin Pharmacol       Date:  2002       Impact factor: 4.335

9.  Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis.

Authors:  P Vallance; A Leone; A Calver; J Collier; S Moncada
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

10.  Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation.

Authors:  Anna R Hemnes; Ivan M Robbins
Journal:  Liver Transpl       Date:  2009-01       Impact factor: 5.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.